Drugs / L-citrulline
L-citrulline
Trials 33
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03542812 | Jul 2019 → Aug 2022 | bronchopulmonary dysplasia, pulmonary hypertension, pulmonary immaturity | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT01683981 | Aug 2012 → Aug 2013 | Eisenmenger syndrome, idiopathic pulmonary arterial hypertension | Masih Daneshvari Hospital | Unknown | No outcome recorded |
| Phase 111 trials | ||||||
| Phase 1 | NCT05722860 | Jan → Nov 2024 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 1 | NCT04979793 | Jul 2021 → Dec 2025 | toxemia of pregnancy | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 1 | NCT06312748 | May 2021 → Sep 2028 expected | diastolic heart failure | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 1 | NCT03952234 | Apr 2021 → Apr 2024 | MELAS syndrome | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02697240 | Feb 2016 → Apr 2017 | sickle cell disease | University of Mississippi Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02659644 | Dec 2015 → Dec 2017 | sickle cell disease | University of Mississippi Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT02314689 | Jan → Dec 2015 | sickle cell disease | Suvankar Majumdar | Completed | No outcome recorded |
| Phase 1 | NCT00743210 | Jan 2010 → Jun 2013 | hypertensive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT00756080 | Sep 2008 → Jan 2009 | — | Nantes University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00742534 | Aug 2008 → Aug 2009 | bronchopulmonary dysplasia | Vanderbilt University | Withdrawn | No outcome recorded |
| Phase 1 | NCT00343954 | — | sickle cell disease | Angiogenix | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01120964 | Sep 2010 → Apr 2012 | atrial septal defect, atrioventricular septal defect, ventricular septal defect | Asklepion Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00201214 | Dec 2003 → Jan 2006 | congenital heart disease | Vanderbilt University | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07617909 | May → Oct 2026 expected | ureterolithiasis, urolithiasis | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 2 | NCT06967428 | Sep 2025 → Jan 2026 overdue | — | Independent Medical Alliance | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06635902 | Dec 2024 → Jun 2028 expected | sickle cell disease | Suvankar Majumdar | Recruiting | No outcome recorded |
| Phase 2 | NCT05259904 | Mar 2023 → Oct 2028 expected | asthma | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT03885245 | Oct 2021 → Dec 2025 overdue | asthma, obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT02018731 | Jun 2013 → Sep 2014 | Becker muscular dystrophy | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2 | NCT00351286 | Mar 2006 → ? | intermittent vascular claudication, peripheral arterial disease | Angiogenix | Unknown | No outcome recorded |
| Phase 2 | NCT00223730 | Oct 2001 → Dec 2007 | cancer | Vanderbilt University | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02801695 | Feb 2017 → Dec 2020 | preeclampsia | Nantes University Hospital | Completed | Missed primary |
| Phase 38 trials · 3 missed | ||||||
| Phase 3 | NCT06989567 | Jul 2025 → Jun 2027 expected | sickle cell disease | Asklepion Pharmaceuticals, LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06212765 | Jan 2024 → Jan 2026 overdue | chronic obstructive pulmonary disease, protein-energy malnutrition | University Hospital, Grenoble | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05253209 | Jun 2022 → May 2024 | atrial septal defect, ostium primum type, atrioventricular septal defect, ventricular septal defect | Asklepion Pharmaceuticals, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02891837 | Aug 2016 → Jun 2019 | acute lung injury | Asklepion Pharmaceuticals, LLC | Completed | Missed primary |
| Phase 3 | NCT02801071 | Jun 2016 → Aug 2017 | postpoliomyelitis syndrome | Dirk Fischer | Completed | No outcome recorded |
| Phase 3 | NCT01995032 | Oct 2013 → Oct 2015 | Duchenne muscular dystrophy | University Hospital, Basel, Switzerland | Completed | Missed primary |
| Phase 3 | NCT01386034 | Jul 2012 → Jul 2015 | chronic intestinal failure | Nantes University Hospital | Completed | Missed primary |
| Phase 3 | NCT00335244 | May 2006 → Dec 2009 | congenital heart defects, multiple types, pulmonary hypertension | Asklepion Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07642505 | Jun → Nov 2026 expected | erectile dysfunction | Beni-Suef University | Recruiting | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 0 | NCT04073381 Background | Oct 2018 → Jul 2020 | — | University of Texas at Austin | Completed | No outcome recorded |
| Phase 0 | NCT01917123 Comparator | Aug 2013 → Mar 2014 | coronary artery disorder | Masih Daneshvari Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04852172 Comparator | Apr 2021 → Feb 2024 | sickle cell disease | Asklepion Pharmaceuticals, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04570384 Comparator | Oct 2020 → Aug 2021 | acute respiratory failure | Asklepion Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01474863 Comparator | Aug 2012 → Mar 2016 | acute lung injury, infectious disease with sepsis | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02638727 Comparator | Dec 2015 → Feb 2016 | vascular disorder | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-citrulline | “This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗30“When administered orally, the NO-L-arginine precursor, L-citrulline, increases NO production in children and adults” PMID 36316628 ↗ Oct 2022 “7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline” NCT03885245 ↗ “The nutrition supplement cocktail will include whey protein, creatine monohydrate, and L-citrulline.” NCT04073381 ↗ “Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes.” NCT01474863 ↗ |
| Known as | citrulline | “This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma...” NCT00742534 ↗8“Citrulline is a drug that is known to increase nitric oxide.” NCT02659644 ↗ |
| Known as | Citrupress | “Intravenous L-Citrulline (Citrupress®) Versus Placebo” NCT01120964 ↗ |
| Known as | L-Citrulline Malate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01683981 ↗ |
| Known as | Turnobi | “Intravenous L-citrulline (Turnobi) administration will safely restore the homeostasis of nitric oxide synthase by increasing both plasma citrulline and arginine levels.” NCT04570384 ↗1“The applicant is developing intravenous L-citrulline (Turnobi™) for treatment of sickle cell disease (SCD).” NCT04852172 ↗ |
| Modality | Other / unclassified | “L-citrulline is a non-protein amino acid that has a direct effect on muscle protein synthesis.” NCT06212765 ↗ |
| Route | Intravenous | “intravenously administered citrulline” PMID 17662768 ↗ Aug 2007 |